XBRANS Stock Overview
A biotechnology company, engages in the development, manufacture, and sale of biosimilars. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Xbrane Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.39 |
| 52 Week High | SEK 59.10 |
| 52 Week Low | SEK 30.60 |
| Beta | 1.17 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.54% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| XBRANS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.6% | 1.9% |
| 1Y | -99.5% | -7.9% | 9.4% |
Return vs Industry: XBRANS underperformed the UK Biotechs industry which returned -21% over the past year.
Return vs Market: XBRANS underperformed the UK Market which returned 10.9% over the past year.
Price Volatility
| XBRANS volatility | |
|---|---|
| XBRANS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: XBRANS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine XBRANS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 75 | Martin Amark | www.xbrane.com |
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma.
Xbrane Biopharma AB (publ) Fundamentals Summary
| XBRANS fundamental statistics | |
|---|---|
| Market cap | SEK 412.96m |
| Earnings (TTM) | -SEK 361.27m |
| Revenue (TTM) | SEK 190.97m |
2.2x
P/S Ratio-1.1x
P/E RatioIs XBRANS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBRANS income statement (TTM) | |
|---|---|
| Revenue | SEK 190.97m |
| Cost of Revenue | SEK 161.51m |
| Gross Profit | SEK 29.46m |
| Other Expenses | SEK 390.73m |
| Earnings | -SEK 361.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 15.43% |
| Net Profit Margin | -189.18% |
| Debt/Equity Ratio | 45.3% |
How did XBRANS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/07 05:07 |
| End of Day Share Price | 2024/04/09 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xbrane Biopharma AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Hans Mähler | Nordea Markets |
| null null | Nordea Markets |